Cell Therapy Transformed Cancer Care. Can it Reset the Immune System?
At EHA 2026 this month, Legend Biotech (NASDAQ: LEGN) is presenting early data on LB2501, an in vivo CAR-T therapy that builds CAR-T cells inside the patient from a single infusion, with no cell manufacturing and no lymphodepleting chemotherapy. The data come from an early, investigator-initiated trial in China: across 12 lymphoma patients, half responded, and at the second dose level all six responded with five reaching complete response. Side effects were mostly low-grade, with no neurotoxicity. Legend is a cell therapy leader worth more than $4 billion, so the stock is not the emerging story. The signal is. CAR-T is becoming simpler, safer, and easier to deliver.
The Bigger Market Is Autoimmune Disease
The same advances are opening a market well beyond oncology. Autoimmune diseases affect tens of millions, and a single infusion that resets the immune system could reduce or replace years of chronic immunosuppression. That is where the emerging, appropriately sized names sit, the next wave forming well beneath the large caps.
Three Names Pushing the Frontier
Cabaletta Bio (NASDAQ: CABA) is furthest along thematically. At EULAR 2026, its CD19 CAR-T rese-cel showed durable, immunomodulator-free responses across myositis, systemic sclerosis, and lupus, and the company named systemic sclerosis as a second registrational indication. Its preconditioning-free program, still in its first patients, aims to drop the chemotherapy step and move treatment outpatient.
Kyverna Therapeutics (NASDAQ: KYTX) is closest to the market, with a rolling FDA submission underway for its CD19 CAR-T, miv-cel, in stiff person syndrome, which would be the first approved CAR-T for an autoimmune disease if cleared. New EULAR data widened the case: in a Phase 1 trial in treatment-refractory rheumatoid arthritis, a single infusion produced deep B-cell depletion and lower disease activity in all six heavily pretreated patients, with most reaching an ACR70 response by week 36 and no high-grade safety events.
Nkarta (NASDAQ: NKTX) takes a different route, using off-the-shelf, allogeneic CAR-NK cells that skip patient-specific manufacturing. In April it reached agreement with the FDA to allow outpatient dosing in community settings, the access question that decides whether cell therapy scales. It is the smallest of the three by market value yet the best capitalized, holding $266.7 million in cash it expects to last into 2029. Initial trial data are due this year.
Where the Risk Actually Sits
None of the three is profitable, so capital is the variable that matters most. Nkarta is funded into 2029, while Cabaletta and Kyverna face the cost of running registrational programs, making runway and potential dilution the risks to track there, not the biology. The direction of travel is clear. CAR-T is moving off the manufacturing line, out of the hospital, and into autoimmune disease, and the emerging names are where that shift shows up first.
